The activity of raltitrexed (Tomudex®) in malignant pleural mesothelioma: An EORTC phase II study (08992)

European Journal of Cancer

Volumn 39, Issue 3, 2003, Pages 353-357

  Baas, P ^a   Ardizzoni, A ^b   Grossi, F ^c   Nackaerts, K ⁱ   Numico, G ^d   Van Marck, E ^e   Van De Vijver, M ^a   Monetti, F ^b   Smid Geirnaerdt, M J A ^f   Van Zandwijk, N ^a   Debruyne, C ^g   Legrand, C ^g   Giaccone, G ^h  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f Stichting Oosterschelde Ziekenhuizen   (Netherlands)

^g EORTC DATA CENTER   (Belgium)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ NONE

Author keywords

Malignant Pleural Mesothelioma, Tomudex, Phase II, EORTC

Indexed keywords

RALTITREXED;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG ACTIVITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; THORAX PAIN; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; QUINAZOLINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME;

EID: 0037304998     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00668-8     Document Type: Article

References (18)

1. Van Meerbeeck J., Debruyne C., Van Zandwijk N.et al. Paclitaxel for malignant mesothelioma. a phase II study of the EORTC LCCG Brit. J. Cancer. 74:1996;961-963.
2. Baas P., Van Meerbeeck J., Groen H.et al. Caelyx in malignant mesothelioma. a phase II EORTC study Ann. Oncol. 11:2000;697-700.
3. Van Meerbeeck J.P., Baas P., Debruyne C.et al. A phase II EORTC study of temozolamide in patients with malignant pleural mesothelioma. Eur. J. Cancer. 38:2002;779-783.
4. Baas P. Chemotherapy for malignant mesothelioma. from doxorubicin to vinorelbine Semin. Oncol. 29:2002;62-69.
5. Ong S.T., Vogelzang N.J. Chemotherapy in malignant mesothelioma. A review. J. Clin. Oncol. 14:1996;1007-1017.
6. Halme M., Knuuttila A., Vehmas T.et al. High dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br. J. Cancer. 80:1999;1781-1785.
7. Solheim O.P., Saeter G., Finnanger A.M., Stenwig A.E. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br. J. Cancer. 65:1992;956-960.
8. Van Cutsem E., Cunningham D., Maroun J.et al. Raltitrexed. current clinical status and future directions Ann. Oncol. 13:2002;513-522.
9. Cunningham D., Zalcberg J., Maroun J.et al. Efficacy, tolerability and management of raltitrexed (Tomudex®) monotherapy in patients with advanced colorectal cancer, a review of phase II/III trials. Eur. J. Cancer. 38:2002;478-486.
10. Scheithauer W., Kornek G.V., Raderer M.et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first line treatment in advanced colorectal cancer. J. Clin. Oncol. 20:2002;165-172.
11. Fizazi K., Caliandro R., Soulie P.et al. Combination raltitrexed (Tomudex®)-oxaliplatin. a step forward in the struggle against mesothelioma? The Institute Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma Eur. J. Cancer. 36:2000;1514-1521.
12. Therasse P., Arbuck S.G., Eisenhauer E.et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI. 92:2000;3. 205-216.
13. A new staging system for malignant mesothelioma. Chest. 108:1995;1122-1126.
14. Fleming T.R. One sample multiple testing procedure for phase II clinical trials. Biometrics. 38:1982;143-151.
15. Hughes A., Calvert P., Azzabi A.et al. Phase I clinical and pharmacokinetic study of pemetrexed in patients with malignant pleural mesothelioma. J. Clin. Onc. 20:2002;3533-3544.
16. Shin DM, Scagliotti G, Kindler H, et al. A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: clinical outcome, role of vitamin suppletion, respiratory symptoms and lung function. Proc ASCO 2002, 21, (abstr 1175).
17. Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single blinded study of pemetrexed and cisplatin versus cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proc ASCO 2002, 2a (abstr 5).
18. EJC. Potential treatment for pleural mesothelioma. Eur J Cancer 2002, 38, 1556.